Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic …
KS McGinnis, JM Junkins-Hopkins, G Crawford… - Journal of the American …, 2004 - Elsevier
BACKGROUND: For nearly 2 decades clinicians have been treating cutaneous T-cell
lymphoma (CTCL) with regimens that combine interferon alfa with retinoid compounds. In
December 1999 a new retinoid, bexarotene, was approved by the US Food and Drug
Administration for the treatment of CTCL. At the manufacturer's recommended dose of
bexarotene (300 mg/m2 of body surface area), it has proven to be a highly effective therapy
for all stages of CTCL. Nevertheless, this dose is typically associated with adverse effects …
lymphoma (CTCL) with regimens that combine interferon alfa with retinoid compounds. In
December 1999 a new retinoid, bexarotene, was approved by the US Food and Drug
Administration for the treatment of CTCL. At the manufacturer's recommended dose of
bexarotene (300 mg/m2 of body surface area), it has proven to be a highly effective therapy
for all stages of CTCL. Nevertheless, this dose is typically associated with adverse effects …